The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Big Pharma now owns 19% at a recent cost of $26.00.
Regeneron shares in the eventual profits while having all the costs covered by payments from this company.
A anti cancer drug promise for tumors is resting on Regeneron and the recent headline says it all:
Regeneron Closes $312 Million Common Stock Sale in Connection with Sanofi-Aventis Collaboration